ArQule Snags $60M From Daiichi Sankyo

12/19/08

ArQule, a Woburn, MA-based cancer drug developer, said today it will receive a $60 million payment through a partnership with Tokyo-based Daiichi Sankyo. The companies will co-develop ARQ-197, a drug designed to block a target on cancer cells called c-Met. Separately, ArQule (NASDAQ: ARQL) said Swiss pharma giant Roche declined an option to develop another drug, called ARQ-761.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @

Next Post

Related Topics

Related Posts

    

Xconomy Events Across the Network

XSITE 2012: The Xconomy Summit on Innovation, Technology & Entrepreneurship

Boston · 6/14/12
8:30 am - 5:00 pm

More Xconomy Events

Xconomy’s Most Popular

  1. Biotech IPOs Start to Show Some Modest Signs of Life
  2. ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
  3. Hey, Silicon Valley: Wake Up and Smell the Robots
  4. From MIT Entrepreneur to Tea Party Leader: The Thomas Massie Story
  5. Announcing Xconomy’s Napa Summit: Keeping America Growing

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.